Protein malnutrition attenuates bone anabolic response to PTH in female rats.
PTH is indicated for the treatment of severe osteoporosis. Elderly osteoporotic patients frequently suffer from protein malnutrition, which may contribute to bone loss. It is unknown whether this malnutrition may affect the response to PTH. Therefore, the aim of the present study was to assess whether an isocaloric low-protein (LP) diet may influence the bone anabolic response to intermittent PTH in 6-month-old female rats. Six-month-old female rats were either pair fed an isocaloric LP diet (2.5% casein) or a normal-protein (NP) diet (15% casein) for 2 weeks. The rats continued on their respective diet while being treated with 5- or 40-μg/kg recombinant human PTH amino-terminal fragment 1-34 (PTH-[1-34]) daily, or with vehicle for 4 weeks. At the end of this period, areal bone mineral density, bone mineral content, microstructure, and bone strength in axial compression of proximal tibia or 3-point bending for midshaft tibia tests were measured. Blood was collected for the determination of IGF-I and osteocalcin. After 4 weeks of PTH-(1-34), the dose-dependent increase of proximal tibia bone mineral density, trabecular microstructure variables, and bone strength was attenuated in rats fed a LP diet as compared with rats on a NP intake. At the level of midshaft tibia cortical bone, PTH-(1-34) exerted an anabolic effect only in the NP but not in the LP diet group. Protein malnutrition was associated with lower IGF-I levels. Protein malnutrition attenuates the bone anabolic effects of PTH-(1-34) in rats. These results suggest that a sufficient protein intake should be recommended for osteoporotic patients undergoing PTH therapy.
Division of Bone Disease (P.A., G.Z., C.L., R.R.), Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, CH 1211 Geneva, Switzerland; and Novartis Institutes for BioMedical Research (J.A.G.), CH 4001 Basel, Switzerland.
P
P
Ammann
G
G
Zacchetti
J A
JA
Gasser
C
C
Lavet
R
R
Rizzoli
D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects*; D005260:Female; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D015675:Osteocalcin / Q000097:blood; D010012:Osteogenesis / Q000187:drug effects*; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy; D010281:Parathyroid Hormone / Q000494:pharmacology* / Q000627:therapeutic use; D011488:Protein Deficiency / Q000150:complications / Q000378:metabolism*; D011897:Random Allocation; D017207:Rats, Sprague-Dawley
D010281:Parathyroid Hormone; D015675:Osteocalcin; D007334:Insulin-Like Growth Factor I